254.49USD+0.04%Mkt Cap: 449.63B $P/E: 124.754d ago
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimm…
Industry Peers
Drug Manufacturers - General$1.02TUSDP/E 40.7
$598.96BUSDP/E 28.8
$305.65BUSDP/E 21.0
$307.25BUSDP/E 35.1
$274.33BUSDP/E 22.0
$268.08BUSDP/E 21.8
$239.58BUSDP/E 24.9
$250.52BUSDP/E 25.0
$211.34BUSDP/E 12.0
$196.55BUSDP/E 25.4
$165.39BUSDP/E 18.1
$141.06BUSDP/E 18.9
$122.85BUSDP/E 16.9
$100.06BUSDP/E 19.4
$81.94BUSDP/E 13.3
$50.52BUSD
$29.52BUSDP/E 21.5
MRV
Marvell Technology, Inc.$20.75BUSDP/E 7.7
$11.51BUSDP/E 18.0
$11.48BUSDP/E 17.9
$11.35BUSDP/E 22.7
$6.96BUSDP/E 15.4
$3.54BUSDP/E 14.5
$2.97BUSDP/E 18.1
$53.73MUSD
$38.66MUSD
ELXR
Elixxer Ltd.$9.51MUSD
ROSE
DocMorris AG—
CELG-RI
Bristol-Myers Squibb Company Ce—
PHOO
Photocure ASA—
FLXN
Horizon Flexible Income ETF—P/E 26.9
FR0000140022
SANOFITP29OCT49—
Indicators:|
Key Statistics
Company
Market Cap449.63B $
Enterprise Value513.20B $
Revenue (TTM)62.82B $
Gross Profit42.96B $
Net Income (TTM)4.23B $
Revenue/Share35.50 USD
Last Price254.49 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees57.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS00287Y1091
Valuation
P/E (Trailing)124.75
P/E (Forward)15.63
PEG0.42
EV/EBITDA17.16
EV/Revenue8.17
P/S7.16
P/B-67.56
EPS (TTM)2.04
EPS (Forward)16.28
52W Range
184.6391% of range261.64
52W High261.64 USD
52W Low184.63 USD
Profitability
Gross Margin70.24%
Oper. Margin32.16%
EBITDA Margin47.62%
Profit Margin6.91%
ROE-129.24%
ROA3.15%
Growth
Revenue Growth12.40%
Earnings Growth-46.20%
Cash Flow & Leverage
Operating CF19.03B $
CapEx (TTM)1.21B $
FCF Margin33.13%
FCF Yield4.63%
Net Debt63.52B $
Net Debt/EBITDA2.12
Balance Sheet
Debt/Equity-20.64
Current Ratio0.80
Quick Ratio0.52
Book Value/Sh-3.7670 USD
Cash/Share5.315 USD
Dividends
Fwd Div Rate6.920 USD
Trail. Div Rate6.740 USD
Div. Yield2.72%
5Y Avg Yield3.60%
Payout Ratio325.98%
Ex-Div DateJul 15, 2026
Pay DateAug 14, 2026
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)266.57 USD
Upside (mean)+4.7%
Target Range200.00 USD – 328.00 USD
$200.00+4.7% to mean$328.00
# Analysts28
Ownership
Shares Out.1.77B
Float1.76B
Insiders0.11%
Institutions76.86%
Short Interest
Short Ratio2.5d
Short % Float1.38%
Short % Out.1.24%
Shares Short21.90M
Short (prev mo.)23.16M
Technical
SMA 50228.11 (+11.6%)
SMA 200223.50 (+13.9%)
Beta0.28
S&P 52W Chg18.27%
Avg Vol (30d)4.77M
Avg Vol (10d)6.49M
Technical Indicators
RSI (14)65.0
MACD8.0108
MACD Signal8.3505
MACD Hist.-0.3397
BB Upper269.35 USD
BB Middle242.24 USD
BB Lower215.13 USD
BB Width22.38%
ATR (14)6.641 USD
Vol Ratio (20d)1.02x